Products
-
Givosiran
Givosiran API is a synthetic small interfering RNA (siRNA) studied for the treatment of acute hepatic porphyria (AHP). It specifically targets the ALAS1 gene (aminolevulinic acid synthase 1), which is involved in the heme biosynthesis pathway. Researchers use Givosiran to investigate RNA interference (RNAi)-based therapies, liver-targeted gene silencing, and the modulation of metabolic pathways involved in porphyria and related genetic disorders.
-
Pegcetacoplan
Pegcetacoplan is a pegylated cyclic peptide that acts as a targeted C3 complement inhibitor, developed for the treatment of complement-mediated diseases such as paroxysmal nocturnal hemoglobinuria (PNH) and geographic atrophy (GA) in age-related macular degeneration.
-
Plozasiran
Plozasiran API is a synthetic small interfering RNA (siRNA) developed for the treatment of hypertriglyceridemia and related cardiovascular and metabolic disorders. It targets the APOC3 gene, which encodes apolipoprotein C-III, a key regulator of triglyceride metabolism. In research, Plozasiran is used to study RNAi-based lipid-lowering strategies, gene-silencing specificity, and long-acting treatments for conditions such as familial chylomicronemia syndrome (FCS) and mixed dyslipidemia.
-
Zilebesiran
Zilebesiran API is an investigational small interfering RNA (siRNA) developed for the treatment of hypertension. It targets the AGT gene, which encodes angiotensinogen—a key component of the renin-angiotensin-aldosterone system (RAAS). In research, Zilebesiran is used to study gene silencing approaches for long-term blood pressure control, RNAi delivery technologies, and the broader role of the RAAS pathway in cardiovascular and renal diseases.
-
Palopegteriparatide
Palopegteriparatide is a long-acting parathyroid hormone receptor agonist (PTH1R agonist), developed for the treatment of chronic hypoparathyroidism. It is a pegylated analog of PTH (1-34) designed to provide sustained calcium regulation with once-weekly dosing.
-
GHRP-6
GHRP-6 (Growth Hormone Releasing Peptide-6) is a synthetic hexapeptide that acts as a growth hormone secretagogue, stimulating the body’s natural release of growth hormone (GH) by activating the GHSR-1a receptor.
API Features :
Purity ≥99%
Manufactured via solid-phase peptide synthesis (SPPS)
Supplied for R&D and commercial use
GHRP-6 is a versatile research peptide for metabolic support, muscle regeneration, and hormonal modulation.
-
GHRP-2
GHRP-2 (Growth Hormone Releasing Peptide-2) is a synthetic hexapeptide and potent growth hormone secretagogue, designed to stimulate the natural release of growth hormone (GH) by activating the GHSR-1a receptor in the hypothalamus and pituitary.
API Features:
Purity ≥99%
Available for R&D and commercial supply, with full QC documentation
GHRP-2 is a valuable research peptide in the fields of endocrinology, regenerative medicine, and age-related therapies.
-
Hexarelin
Hexarelin is a synthetic growth hormone secretagogue peptide (GHS) and potent GHSR-1a agonist, developed to stimulate endogenous growth hormone (GH) release. It belongs to the ghrelin mimetic family and is composed of six amino acids (a hexapeptide), offering enhanced metabolic stability and stronger GH-releasing effects compared to earlier analogs like GHRP-6.
API Features :
Purity ≥ 99%
Produced via solid-phase peptide synthesis (SPPS)
GMP-like standards, low endotoxin and solvent residues
Flexible supply: R&D to commercial scale
-
Melanotan II
API Features:
High purity ≥ 99%
Synthesized via solid-phase peptide synthesis (SPPS)
Low endotoxin, low residual solvents
Available in R&D to commercial scale -
Melanotan 1
Melanotan 1 API is produced using solid phase peptide synthesis (SPPS) technology under strict GMP-like quality control conditions.
-
High purity ≥99%
-
Solid-phase peptide synthesis (SPPS)
-
GMP-like manufacturing standards
-
Full documentation: COA, MSDS, stability data
-
Scalable supply: R&D to commercial levels
-
-
MOTS-C
MOTS-C API is produced under strict GMP-like conditions using solid phase peptide synthesis (SPPS) technology to ensure its high quality, high purity and high stability for research and therapeutic use.
Product Features:Purity ≥ 99% (confirmed by HPLC and LC-MS),
Low endotoxin and residual solvent content,
Produced in accordance with ICH Q7 and GMP-like protocols,
Can achieve large-scale production, from milligram-level R&D batches to gram-level and kilogram-level commercial supply. -
Ipamorelin
Ipamorelin API is prepared by high-standard **solid phase peptide synthesis process (SPPS)** and undergoes strict purification and quality testing, suitable for early pipeline use in scientific research and development and pharmaceutical companies.
Product features include:
Purity ≥99% (HPLC test)
No endotoxin, low residual solvent, low metal ion contamination
Provide a full set of quality documents: COA, stability study report, impurity spectrum analysis, etc.
Customizable gram-level~kilogram-level supply